JNJ-90009530: A phase 1 trial of JNJ-90009530 in people with relapsed or refractory B-cell Non-Hodgkin lymphoma
This trial is testing the treatment JNJ-90009530, which is a CAR-T therapy, in people with B-cell Non-Hodgkin lymphoma (NHL) which has returned after (relapsed) or not responded (refractory) to treatment.
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05784441
Trial aim and background
The aim of this trial is to test the treatment JNJ-90009530 in people with relapsed or refractory NHL. It aims to see what a safe, well tolerated dose is, and can it successfully treat NHL, and for how long.
JNJ-90009530 is an autologous anti-CD20 CAR-T cell therapy. CAR-T cell therapy uses cells from your own immune system to fight the lymphoma. The cells called T-cells are collected, changed so that they can recognise and stick to the lymphoma cells, and then given back to you.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with relapsed or refractory B-cell NHL may be eligible for this trial.
Locations
Recruitment is taking place at the University College London Hospitals.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05784441
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.